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y101610@npc.gov.Abstract Strychnos nux-vomica L. has been frequently used in traditional Chinese medicine but
has high acute toxicity. It is commonly taken with Glycyrrhizae radix to decrease its toxicity but the
mechanism of this interaction is unknown. In this work, the mRNA expression and the activity of
four cytochrome P450 (CYP) enzymes representative of four subfamilies (CYP1A, CYP3A,
CYP2C and CYP2E) were determined ex vivo in rat livers from groups of Wistar rats orally
administered strychnine hydrochloride (SH) at three doses (0.1, 0.3 and 0.9 mg/kg/day) alone and,
at the highest dose, in combination with glycyrrhetinic acid (GA, 25 mg/kg/day) or liquiritin (LQ,
20 mg/kg/day) once a day for 7 consecutive days. Compared to control, the mRNA expressions of
CYP3A1, 1A2 and 2E1 were higher in rats receiving the highest dose of SH but lower for CYP3A1
and CYP2E1 in rats receiving the SHþGA and SHþLQ combinations. CYP2E1 activity was
higher and CYP2C, CYP3A and CYP1A2 activities were lower in rats receiving the highest dose of
SH. In contrast CYP1A2 and CYP2C activities were higher and CYP2E1 and CYP3A activities
lower in rats receiving the SHþGA combination. CYP2E1 and CYP3A activities were also lower in
rats receiving the SHþLQ combination. The results show that treatment with SH for 7 days affects
the expression and the activity of CYP enzymes and that coadministration of GA and LQedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
tute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
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Figure 1 Structures of
Qian Gao et al.122modulates these effects. This modulation may explain the role of Glycyrrhizae radix in reducing the
acute toxicity of Strychnos nux-vomica L.CYPs enzymes.
& 2011 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Strychnos nux-vomica L. is a highly toxic herbal preparation
frequently used as an important ingredient of many traditional
Chinese medicines. One example is Bi-Qi capsules originating
with the great Han Dynasty physician, Hua Tuo, for the
treatment of joint pain, arthritis and rheumatic diseases1.
In clinical use, S. nux-vomica L. is commonly taken with
Glycyrrhizae radix to decrease its toxicity but the mechanism
of this detoxicating action remains unclear.
Strychnine (STN, Fig. 1A), the major pharmacodynamic
component of S. nux-vomica L., is a well-known potent antago-
nist of glycine receptors in the vertebrate central nervous system2
and a strong blocker of various types of muscle and neuronal
nicotinic acetylcholine receptors3. Because of its activity in spinal
cord synapses and despite extensive research into its effects on the
nervous system, its therapeutic window is very narrow4. Previous
studies indicate that STN is rapidly absorbed from the gastro-
intestinal tract, rapidly distributed to tissues with very little
plasma protein binding5, and eliminated mainly by hepatic
metabolism6. A recent publication from our group indicates that
the major enzyme responsible for STN metabolism in rat liver
microsomes is CYP3A1 followed in importance by CYP2E17.
G. radix is the most important detoxicating herbal preparation
used in traditional Chinese medicine. The dissolution rate of
STN and brucine from the co-decoction of G. radix and
S. nux-vomica L. is signiﬁcantly slower than from S. nux-vomica
L. such that its toxicity is reduced8. Studies have shown that the
extract of G. radix can attenuate free radical-induced oxidative
damage in the kidney and prevent the carcinogenesis induced by
toxicants and hormones9. It is well known that ﬂavonoids and
pentacyclic triterpene saponins including liquiritin (LQ, Fig. 1C),strychnine (A), strychnine hydroglycyrrhizic acid (GIA) and glycyrrhetic acid (GA, Fig. 1D) are
the major active constituents of G. radix. GIA is hydrolyzed by
glucuronidase in the intestinal microbiota to its active aglycone
GA, which is then absorbed into the blood10. Liquiritigenin, the
aglycone of LQ, mediates signiﬁcant protection against the acute
liver injury induced by acetaminophen (APAP) during glu-
tathione (GSH) depletion, and exerts a neuroprotective effect
and inhibitory action on cholinesterase activity11.
CYP1A1 and 1A2 are the most important members of the
CYP1A subfamily, but only the CYP1A2 gene is constitutively
expressed in rat liver and induced by aromatic hydrocar-
bons12. CYP2E1 is one of the few drug metabolizing enzymes
that is reasonably conserved between mammalian species, and
has very broad substrate speciﬁcity13. Like CYP1A2, it is
abundantly expressed in human and rodent liver and may play
an important role in activating environmental carcino-
gens14,15. CYP2C11 is the predominant CYP isoform in male
rat liver comprising 450% of its total CYP content16 and
catalyzing the oxidation of several important xenobiotics12.
It is well known that the induction or the inhibition of CYP
enzymes is an important mechanism of drug interactions. For this
reason, the aim of the present study was to assess the effect of
treatment with STN alone and in combination with GA and LQ
on the mRNA expression and the activity of four important drug
metabolizing CYPs (CYP3A, 1A2, 2E1 and 2C) in rat liver ex vivo.2. Materials and methods
2.1. Drugs and reagents
Materials (suppliers) include NADPH (Roche Co., Switzerland);
TransStart Green qPCR SuperMix (TransGen Biotech., China);chloride (B), liquiritin (C) and glycyrrhetic acid (D).
Determination of CYP enzymes mRNA expression and activity in rat 123TRIzol reagent (Invitrogen, USA); strychnine hydrochloride,
resoruﬁn sodium salt, 4-nitrocatechol, 4-nitrophenol, testoster-
one and tolbutamide (Sigma-Aldrich, USA); ethoxyresoruﬁn,
4-hydroxytolbutamide, 6b-hydroxytestosterone (TRC, Canada);
glycyrrhetinic acid (National Institute for the Control of
Pharmaceutical and Biological Products, China); liquiritin
(Chengdu Mansite Chemical Co., China ). All other laboratory
chemicals were of the highest purity available from commercial
suppliers and were used as received.
2.2. Animals and drug treatment
All experimental procedures were conducted in accordance with
guidelines for the care and the use of laboratory animals and
approved by the Animal Care Committee of Hubei University.
Male Wistar rats (180–200 g, Experimental Animal Center of
Hubei province, Certiﬁcate Number 00007211) were housed for 7
days under SPF grade laboratory conditions (2572 1C, 6075%
relative humidity, 12 h light–dark cycle) with free access to food
and water throughout the study. A total of 18 rats were
randomly divided into 6 groups (n¼3/group) and given an oral
dose of A: saline containing 0.5% CMC; B: SH 0.1 mg/kg/day;
C: SH 0.3 mg/kg/day; D: SH 0.9 mg/kg/day; E: SH 0.9 mg/kg/
day plus GA 25 mg/kg/day; and F: SH 0.9 mg/kg/day plus LQ
20 mg/kg/day once a day for 7 consecutive days. Animals were
sacriﬁced 1 h after the last dose and livers were immediately
removed and sliced into two parts. One part was weighed,
washed in cold homogenization buffer (0.25 mol/L sucrose,
0.01 mol/L tris–HCl, 1 mmol/L EDTA, pH 7.4) and used to
prepare rat liver microsomes (RLM)17. The other was stored in
liquid nitrogen until used for mRNA extraction.
2.3. Assay for CYP mRNA expression
RNA isolation and reverse transcription (RT) were carried out
using Trizol and the SuperScript III First-Strand Synthesis
System, respectively, following the supplier’s instructions
(Invitrogen, USA). The concentration of total RNA was
determined using the Biophotometer (Eppendorf AG,
Hamburg, Germany). QRT-PCR assay of mRNA expression
was performed using TransStart Green qPCR SuperMix accord-
ing to the manufacturer’s instructions. The primers of the tested
CYPs were designed using the Primers 3.0 program (National
Biosciences) and are depicted in Table 1. Thermal cycling and
ﬂuorescence detection was performed using the MiniOpticon
Monitor Sequence Detection System with Opticon Monitor 3
(Bio-Rad, USA). The glyceraldehyde 6-phosphate dehydrogen-
ase (GAPDH) gene was used as a housekeeping gene for
normalization. The reaction mixture (20 mL) for each CYPTable 1 Real-time PCR conditions of the four CYPs tested.
Gene Forward primers
GAPDH TTCAACGGCACAGTCAAG
CYP3A1 GGAAATTCGATGTGGAGTGC
CYP1A2 TGTCACCTCAGGGAATGCT
CYP2E1 GCTGTCAAGGAGGTGCTAC
CYP2C11 AGCTCTTGTTGATCTAGGAG
GAPDH—glyceraldehyde 6-phosphate dehydrogenase.
Primers for GAPDH, CYP3A1, CYP1A2, CYP2E1, CYP2C11 were dwas composed of TransStart Green qPCR SuperMix (10 mL),
primer (0.25 mmol/L) and the RT product from 25 ng of RNA
(1 mL). After incubation at 95 1C for 5 min, the PCR reaction
was performed for 42 cycles: denaturation at 94 1C for 50 s,
annealing at 58 1C for 40 s and extension at 72 1C for 20 s. The
mRNA level is expressed as the ratio to GAPDH.
2.4. Assay for CYP activity
2.4.1. Method validation
Selectivity of the assays for each metabolite was investigated
by analyzing six individual blank RLM samples. The chro-
matogram of each blank RLM sample was compared with
that of a sample at the limit of quantitation (LOQ). Fluores-
cence and absorbance of each blank RLM sample were also
compared with those of a sample at the LOQ.
Linearity of the assays was assessed by preparing calibra-
tion curves based on 8 concentrations of 6b-hydroxytestoster-
one (0.5–32.0 mmol/L), resoruﬁn (0.05–0.40 mmol/L), 4-
nitrocatechol (0.5–100.0 mmol/L) and 4-hydroxytolbutamide
(0.4–25.6 mmol/L) in RLM mixture without NADPH on six
separate occasions.
Accuracy (as relative error, RE) and precision (as relative
standard deviation, RSD) of each metabolite were investigated
by the analysis of 6 replicates of quality control (QC) samples
(6b-hydroxytestosterone 1.0, 4.0 and 16.0 mmol/L; resoruﬁn
0.05, 0.10 and 0.40 mmol/L, 4-nitrocatechol 0.5, 4.0 and
16.0 mmol/L; 4-hydroxytolbutamide 0.8, 3.2 and 12.8 mmol/L)
in NADPH-free RLM solution on three different days. Con-
centrations were determined using a calibration curve con-
structed on the same day. The criteria used to assess the
suitability of precision and accuracy were RSDo15% and
accuracy715%. The recovery of each metabolite was examined
by comparing the mean peak areas of QC samples with peak
areas determined from calibration curves.
2.4.2. Assay for CYP activities
CYP activities in the RLM from each group were determined
based on testosterone 6b-hydroxylation (CYP3A)18, ethoxy-
resoruﬁn-O-deethylation (CYP1A2)19, paranitrophenol hydro-
xylation (CYP2E1)20 and tolbutamide hydroxylation
(CYP2C)21 as follows:
CYP3A: The reaction mixture consisted of hepatic microsomal
protein (0.2 mg), 5 mmol/L MgCl2, 0.25 mmol/L testosterone in
PBS buffer (0.1 mmol/L, pH 7.4) at a ﬁnal volume of 0.2 mL. The
reaction was initiated by adding NADPH(1 mmol/L), incubated
for 10 min at 37 1C and terminated by adding 400 mL cold
methanol. The mixture was then vortexed for 3 min, centrifuged
at 12,000 g for 10 min and the supernatant was transferred andReverse primers Gene ID
CACACCCATCACAAACAT 24383
AGGTTTGCCTTTCTCTTGCC 25642
GACCACCGTTGTCTTTGTAG 24279
GCCTCATTACCCTGTTTCC 25086
GGGAAGTAATCAATAATGGC 378476
esigned using the Primers 3.0 program (National Biosciences).
Qian Gao et al.124evaporated (BioTron Ecospin 3180C LABCONCO) at 40 1C. The
residue was dissolved in mobile phase (38% water :62%methanol)
and analyzed for 6b-testosterone by HPLC using an Inertsil ODS-
C18 reversed phase column (4.6 mm 150 mm, particle size 5 mm)
(Dikma Technologies Inc., USA), with a ﬂow rate of 0.8 mL/min
and a detection wavelength of 247 nm.
CYP1A2: The reaction mixture consisted of hepatic micro-
somal protein (0.08 mg), 5 mmol/L MgCl2, 6.5 mmol/L ethoxy-
resoruﬁn in a ﬁnal volume of 0.2 mL. The reaction was
initiated by adding NADPH (1 mmol/L), incubated for
10 min at 37 1C and terminated by adding 400 mL cold
methanol. Following centrifugation (12,000 g, 10 min),
the supernatant was analyzed for resoruﬁn using a Multi-
function Microplate Reader (TriStar LB 941, Berthold Tech-
nologies, Germany) with excitation and emission wavelengths
of 530 and 586 nm, respectively.
CYP2E1: The 200 mL reaction mixture contained 0.2 mg/mL
microsomal protein, 1 mmol/L NADPH and 0.5 mmol/L
p-nitrophenol in 0.1 mol/L PBS buffer (pH 7.2). The reaction
was terminated by adding 400 mL cold methanol. After vortexing
and centrifuging (12,000 g, 10 min), NaOH (10 mol/L, 20 mL)
was added to the supernatant. After centrifuging (12,000 g,
10 min) a second time, the absorbance of 4-nitrocatechol in the
supernatant was determined immediately at 530 nm using aFigure 2 Effects of treatment with strychnine hydrochloride on mRN
liver ex vivo. Analyses were performed in triplicate. Data are the me
different from control by two-way analysis of variance and the St
Signiﬁcantly different from SH (0.9 mg/kg/day) alone by SH group
multiple range test (##Po0.01).Multifunction Microplate Reader (TriStar LB 941, Berthold
Technologies, Germany).
CYP2C: This was measured by incubating hepatic micro-
somes (0.4 mg protein) with tolbutamide (0.25 mmol/L) and
NADPH (1 mmol/L) for 45 min at 37 1C in a ﬁnal volume of
400 mL. The reaction was terminated by adding 800 mL cold
solution of 10% acetic acid plus 600 mL methanol. After
vortexing for 3 min and centrifuging (12,000 g for 10 min),
the supernatant was evaporated (BioTron Ecospin 3180C
LABCONCO) at 40 1C. The residue was dissolved in mobile
phase (30% acetonitrile, 70% water containing 0.1% acetic
acid) and 4-hydroxytolbutamide analyzed by HPLC using a
Inertsil ODS-C18 reversed phase column (4.6 mm 150 mm,
particle size 5 mm) (Dikma Technologies Inc., USA), with a
ﬂow rate of 0.8 mL/min and a detection wavelength of 230 nm.2.5. Data analysis
All data are presented as mean7standard deviation (SD).
Differences in parameters between groups were assessed by
two-way analysis of variance and the Student–Newman–Keuls
multiple range test (Sigma StatTM, SPSS Science, Chicago, IL,
USA). The level of statistical signiﬁcance was set at Po0.05.A expression of CYP3A1, CYP1A2, CYP2C11 and CYP2E1 in rat
an7S.E.M. of three different RLM in same group. Signiﬁcantly
udent-Newman-Keuls multiple range test (nPo0.05, nnPo0.01).
two-way analysis of variance and the Student-Newman-Keuls
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3.1. CYP mRNA expression
The effect of treatment on mRNA expression of CYP3A1,
CYP1A2, CYP2E1 and CYP2C11 in rat liver ex vivo is shown
in Fig. 2. The results reveal that SH at medium and high doses
caused 3.1-fold and 8.1-fold increases, respectively, in CYP3A1
mRNA expression and 3.8-fold and 7.4-fold increases, respec-
tively, in CYP2E1 mRNA expression as compared to control.
However, administration of SHþGA and SHþLQ decreased
the mRNA expression of CYP3A1 (3.4-fold and 4.9-fold,
respectively) and CYP2E1 (3.9-fold and 4.6-fold, respectively)
as compared with the high SH dose group. In addition, SH at
the low and medium doses caused 2.7-fold and 13.9-fold
decreases, respectively, in CYP2C11 mRNA expression as
compared to control whereas administration of SHþGA
increased CYP2C11 mRNA expression 3.1-fold as compared
with the high SH dose group. All treatments caused slightFigure 3 Representative chromatograms for 6b-hydroxytestosterone;
6b-hydroxytestosterone (0.5 mmol/L); (C) an RLM sample incub
testosterone; 2. testosterone).
Figure 4 Representative chromatograms for 4-hydroxyltolbutamide;
4-hydroxyltolbutamide (0.4 mmol/L); (C) an RLM sample incubated
tolbutamide).increases in CYP1A2 mRNA expression ranging from 1.6-fold
to 2.6-fold as compared to control.3.2. CYP activities
3.2.1. Method validation
Figs. 3 and 4 show typical chromatograms of 6b-hydroxy-
testosterone and 4-hydroxytolbutamide in RLM incubation
solutions and in controls, respectively. As shown in Fig. 3, no
signiﬁcant interference was observed in the controls. The
retention times of 6b-hydroxytestosterone and 4-hydroxytol-
butamide were 5.48 and 5.44 min, respectively.
Resoruﬁn ﬂuorescence and 4-nitrocatechol absorbance of
each blank RLM sample are signiﬁcantly different from the
values of samples at the LOQs (data not shown).
Typical equations of calibration curves determined by
weighted (1/x2) least squares linear regression are 6b-hydro-
xytestosterone, y¼429.19xþ55.14 (r¼0.9995); resoruﬁn,(A) a blank RLM sample; (B) a blank RLM sample spiked with
ated with of testosterone (0.25 mmol/L); (1. 6b-hydroxylated
(A) a blank RLM sample; (B) a blank RLM sample spiked with
with tolbutamide (0.25 mmol/L); (1. 4-hydroxyltolbutamide; 2.
Table 3 Effect of treatment with strychnine hydrochloride on CYP activities in RLM.
CYP
isoform
Activity
(pmol/L/mg/min)
Control SH (0.1 mg/
kg/day)
SH (0.3 mg/
kg/day)
SH (0.9 mg/
kg/day)
SH 0.9þGA
(25 mg/kg/day)
SH 0.9þLQ
(20 mg/kg/day)
CYP3A 6b Testo-OH 107.675.2 86.472.9n 64.972.8nn 57.673.8nn 33.476.6 28.975.6
CYP1A2 EROD 7.570.7 6.871.7 5.570.2nn 5.670.8n 7.670.6## 5.770.7
CYP2E1 PNP-OH 61.379.4 48.078.0 81.378.0n 94.777.7nn 48.077.7## 41.3710.2##
CYP2C Tol-OH 25.272.2 7.773.9nn 5.470.9nn 10.671.2nn 16.472.0# 10.972.2
Analyses were performed in duplicate. Data are mean7S.E.M. (n¼3).
nSigniﬁcantly different from control by two-way analysis of variance and the Student–Newman–Keuls multiple range test (Po0.05).
nnSigniﬁcantly different from control by two-way analysis of variance and the Student–Newman–Keuls multiple range test (Po0.01).
#Signiﬁcantly different from SH (0.9 mg/kg/day) alone by two-way analysis of variance and the Student–Newman–Keuls multiple range
test (Po0.05).
##Signiﬁcantly different from SH (0.9 mg/kg/day) alone by two-way analysis of variance and the Student–Newman–Keuls multiple range
test (Po0.01).
Table 2 Intra- and inter-day precisions and recoveries for the four CYP metabolites (data are mean7S.D., n¼6).
Metabolite Concentration
(mmol/L)
Intra-day
RSD (%)
Inter-day
RSD (%)
Relative recovery (%)
(mean7S.D.)
6b-Hydroxytestosterone 1.0 2.43 1.91 88.772.1
4.0 3.27 3.23 99.577.9
16.0 0.67 1.01 104.071.1
Resoruﬁn 0.05 5.88 4.08 102.871.5
0.10 1.00 3.13 110.370.6
0.40 2.07 1.27 96.970.7
4-Nitrocatechol 0.5 0.20 0.20 99.970.1
4.0 2.07 2.77 100.271.0
16.0 0.85 0.36 99.771.8
4-Hydroxytolbutamide 0.8 1.28 2.76 98.570.1
3.2 0.58 1.28 105.272.1
12.8 0.19 0.41 103.871.1
Qian Gao et al.126y¼69,438x80.414 (r¼0.9999); 4-nitrocatechol, y¼0.0025xþ
0.0009 (r¼0.9995); 4-hydroxytolbutamide, y¼118.18xþ
42.585 (r¼0.9999). All calibration curves showed excellent
linearity in the concentration ranges used. The intra-day and
inter-day precisions were o15% for each analyte and recov-
eries were precise and reproducible (Table 2).
3.2.2. Effect of treatment
The effect of treatment on CYP activity in rat liver ex vivo is
shown in Table 3. Compared to control, SH at low, medium and
high doses decreased CYP3A-associated 6b-hydroxytestosterone
formation by 19.7%, 39.7% and 46.5%, respectively, CYP1A2-
associated resoruﬁn formation by 9.3%, 26.7% and 25.3%,
respectively, and CYP2C-associated hydroxytolbutamide forma-
tion by 69.4%, 78.6% and 54.5%, respectively. Regarding
CYP2E1, SH at the low dose caused a 21.3% decrease in
CYP2E1-associated p-nitrocatechol formation whereas at the
medium and high doses 32.6% and 54.5% increases, respec-
tively, were observed. Administration of SHþGA caused 42.0%
and 49.3% decreases in CYP3A-associated 6b-hydroxytestoster-
one and CYP2E1-associated p-nitrocatechol formation,respectively, and 35.7% and 54.7% increases in CYP1A2-
associated ethoxyresoruﬁn and CYP2C-associated hydroxytol-
butamide formation, respectively, as compared to the high SH
dose group. Administration of SHþLQ caused 49.8% and
56.4% decreases in CYP3A-associated 6b-hydroxytestosterone
and CYP2E1-associated p-nitrocatechol formation, respectively4. Discussion
In the present work, the oral doses of SH were chosen on the
basis of the rat oral LD50 value of STN (2.35 mg/kg)
22 and the
recommended clinical dose (1–3 mg at any one time) of
strychnine nitrate injection (GUOYAOZHUNZI of China:
H31021529). Preliminary tests showed that more than 50% of
rats died when administered an SH dose 2.5-fold greater than
the LD50 of STN and that a dose of approximately 1/3 of the
LD50 of STN was safe to use in experiments. The dose of GA
was chosen on the basis of the daily recommended dose of
diammonium glycyrrhizinate capsules (450 mg/kg/day)23, which
equates to a daily dose of 25 mg/kg/day in rat. Finally, the dose
Determination of CYP enzymes mRNA expression and activity in rat 127of LQ was chosen based on its reported effective dose24. In
order to increase the probability of observing a change in CYP
activity between SH alone and SH in combination, only the
high dose of SH was used in combinations with GA and LQ.
Compared to control, the changes in CYP3A and CYP1A2
activities and mRNA expression levels in rats treated with SH
at the three doses were in opposite directions whereas the
corresponding changes in CYP2C and CYP2E1 (except for
the low dose of SH) were in the same direction. The results
suggest that SH affects CYP3A and CYP1A2 at the
post-transcriptional level25,26, and affects CYP2C and
CYP2E1 at the transcriptional level27,28. The coadministration
of GA caused obvious changes in mRNA expression and
enzyme activities of CYP3A and CYP2E1 as did coadminis-
tration of LQ. The results suggest that GA and LQ interact
with SH at the level of mRNA expression and activity.
Our previous studies indicated that STN was metabolized
mainly by CYP3A and to a small extent by CYP2E1 in rat7,
and mainly by CYP3A4 and to small extents by CYP2C19 and
CYP2C9 in human29. CYP3A1 in rat has a very high
homology with CYP3A4 in human30 such that testosterone,
as the speciﬁc probe substrate of CYP3A4, is also a suitable
probe of CYP3A131. CYP2C11 in rat is also highly similar to
CYP2C9 in human30, which is well known to affect the
toxicity of CYP2C9-dependent drugs with low therapeutic
indices31. The present study showed that SH at the high dose
level signiﬁcantly decreased the activities of CYP3A, CYP1A2
and CYP2C, and signiﬁcantly increased CYP2E1 activity as
compared to control. The coadministration of GA or LQ
decreased CYP3A (although the difference was not signiﬁcant)
and CYP2E1 activities. In contrast, the activities of CYP1A2
and CYP2C were signiﬁcantly increased by the coadministra-
tion of GA as compared to SH alone. The results suggest that
the elimination of SH in vivo is decreased by GA and LQ
due to the decrease in CYP3A and CYP2E1 activities but
increased by GA due to the increase in CYP2C activity.
Therefore, it appears that coadministration of GA and LQ
with SH can modulate the pharmacokinetics of SH.
5. Conclusions
Changes in CYP activities can lead to desirable or undesirable
changes in the pharmacological effects of clinically used drugs,
especially in the case of drugs with low therapeutic indices. The
present study provides important information related to the
metabolic interaction between STN and GA or LQ and indicates
that a drug–drug interaction may occur when S. nux-vomica L. is
used in combination with G. radix. However, details of the actual
mechanism of the interaction remain to be clariﬁed.
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